Ke Li

Ke Li

Auto-generated profile, based on publicly available information

Ke Li

Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, 214063, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2016 in Molecules
Verified
Journal Article
Open access
PDF file
LQLing Qiu
Ling Qiu
HLHong Liu
Hong Liu
KLKe Li
Ke Li
GLGaochao Lv
Gaochao Lv
HYHui Yang
Hui Yang
JLJianguo Lin
Jianguo Lin
Two new platinum(II)-based complexes bearing a bone-targeting group were synthesized and characterized. They both have excellent affinity for hydroxyapatite (HA), which is abundant in human bone tissues. Their antitumor activities against five human cancer cell lines (U2OS, A549, HCT116, MDA-MB-231 and HepG2) were evaluated and compared with cisplatin (CDDP). Though the antitumor efficacies of new complexes are lower than that of CDDP, they show higher selectivity against the HepG2 hepatoma cell line than the L02 normal liver cell line. Morphology studies exhibited typical characteristics of cell apoptosis and the cell cycle distribution analysis indicated that the complexes can inhibit cancer cells by inducing cell cycle arrest at the G2/M phase, a similar mechanism of action to CDDP.

26 April 2018 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
XZXueyu Zhao
Xueyu Zhao
GLGaochao Lv
Gaochao Lv
YPYing Peng
Ying Peng
QLQingzhu Liu
Qingzhu Liu
XLXi Li
Xi Li
JLJianguo Lin
Jianguo Lin